Visceral Pain Treatment Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Visceral Pain Treatment Market is Segmented by Drug Class (Analgesics, Pain Modifiers, Antispasmodics, and More), Indication (Irritable Bowel Syndrome, and More), Route of Administration (Oral, Injectable & Infusion, Topical, and Others), Distribution Channel (Hospital Pharmacies, and More), End User (Hospitals, and More), and Geography (North America, Europe, and More). The Market and Forecast are in Terms of Value (USD).

Visceral Pain Treatment Market Size and Share

Visceral Pain Treatment Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Visceral Pain Treatment Market Analysis by Mordor Intelligence

The Visceral Pain Treatment Market size is expected to increase from USD 16.83 billion in 2026 to USD 17.98 billion in 2027 and reach USD 25.03 billion by 2032, growing at a CAGR of 6.84% over 2027-2032.

The expanding prevalence of functional bowel disorders, inflammatory bowel disease, chronic pancreatitis, and pelvic pain conditions is increasing demand for care across a wider patient base. The visceral pain treatment market is also moving away from broad analgesic use toward therapies matched to inflammatory, neural, or local tissue mechanisms. This shift favors companies that can generate durable clinical outcomes and secure use earlier in treatment pathways. Biologics, targeted therapies, diagnostic tools, and neuromodulation devices are creating new opportunities, although access remains limited by diagnostic uncertainty, reimbursement variation, and biosimilar competition. The resulting market is shaped by the balance between established oral prescriptions and higher-value specialty treatments. The visceral pain treatment market depends on timely diagnosis and effective specialty access.

Key Report Takeaways

  • By drug class, analgesics held 38.42% of the visceral pain treatment market share in 2026, while biologics and targeted immunotherapies are forecast to grow at a 7.21% CAGR through 2032.
  • By indication, irritable bowel syndrome accounted for 34.15% of the visceral pain treatment market share in 2026, while inflammatory bowel disease is projected to expand at a 7.57% CAGR through 2032.
  • By route of administration, oral formulations held 68.27% market share in 2026, while injectable and infusion formats are forecast to grow at an 8.43% CAGR through 2032.
  • By distribution channel, retail pharmacies held 48.34% market share in 2026, while online pharmacies are projected to expand at an 8.92% CAGR through 2032.
  • By end user, hospitals accounted for 46.39% market share in 2026, while specialty clinics are forecast to grow at a 9.36% CAGR through 2032.
  • By geography, North America held 37.45% market share in 2026, while Asia-Pacific is projected to expand at a 9.74% CAGR through 2032 in the visceral pain treatment market.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Visceral Pain Treatment Market Segment Analysis

By Drug Class:

Biologics Redefine Growth

Analgesics held 38.42% of the share in 2026, reflecting established use of NSAIDs, opioid-based formulations, and other conventional medicines. Biologics and targeted immunotherapies are the fastest-growing class at a 7.21% CAGR through 2032. The category is supported by anti-integrin and anti-IL-23 programs used in IBD. SKYRIZI generated USD 6.4 billion in global IBD sales in 2025, showing the revenue potential of early treatment placement.

The visceral pain treatment market size for biologics is supported by the continued move toward disease-state specificity. Histamine receptor antagonists and pH-sensitive opioids are candidates intended to target mechanisms present in affected tissue. These approaches may reduce off-target effects that limit chronic use of conventional analgesics. In IBD, biologics increasingly compete on composite remission, durability, and earlier therapy use. Conventional products will remain important because they address a wider, largely oral treatment base.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Visceral Pain Treatment Market Share by Drug Class, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Visceral Pain Treatment Market Share by Drug Class, 2026

By Indication:

IBD Gains Momentum While IBS Retains Scale

Irritable bowel syndrome accounted for 34.15% of the share in 2026. Its scale is supported by a large treatable population, a broad oral prescription base, and expanded use of LINZESS in pediatric IBS-C. LINZESS reached 234 million prescription capsules in 2025, up 11% year over year. IBD is the fastest-growing indication at a 7.57% CAGR through 2032 because biologic therapy use is deepening in Crohn's disease and ulcerative colitis. Lilly reported that 78% of eligible Omvoh-treated ulcerative colitis patients in the LUCENT-3 extension maintained corticosteroid-free clinical remission at 4 years.

Chronic pancreatitis, interstitial cystitis or bladder pain syndrome, and chronic prostatitis or pelvic pain syndrome have fewer established treatment choices. A 2025 review describes nociceptive, neuropathic, and nociplastic pain mechanisms that require different treatment strategies. Ironwood stopped development of IW-3300 after reviewing Phase II data for interstitial cystitis or bladder pain syndrome. The decision shows the clinical risk of expansion outside established IBS and IBD pathways. Multimodal protocols may become more relevant where no single intervention sufficiently addresses pain.

By Route of Administration:

Injectable Growth Reflects Biologic Adoption

Oral formulations held 68.27% of the share in 2026 because analgesics, antispasmodics, and many small molecules are administered orally. Injectable and infusion formats are forecast to grow at an 8.43% CAGR through 2032. This growth is driven by biologics that use subcutaneous injection or intravenous infusion. AbbVie licensed NXE0033744, an investigational oral EP4 receptor agonist for IBD, from Nxera Pharma in November 2026 for USD 100 million upfront.

Subcutaneous options can reduce hospital resource use and improve convenience for maintenance treatment. Takeda reported that U.S. Entyvio pen volume rose 20% sequentially in the first half of FY2025 and represented 9% of U.S. Entyvio sales by October 2025. Topical and other routes continue to serve narrower needs such as localized pelvic pain and bladder instillation treatment. Halozyme and Takeda announced a collaboration to use ENHANZE technology with vedolizumab, supporting development of a subcutaneous formulation. The visceral pain treatment market will continue to use several routes because patient preferences and disease severity vary widely.

Segment this market the way your business does.

Get tailored market insights for your requirements.

Visceral Pain Treatment Market Share by Route of Administration, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Visceral Pain Treatment Market Share by Route of Administration, 2026

By Distribution Channel:

Online Pharmacies Gain Specialty Roles

Retail pharmacies held 48.34% of market share in 2026 because they remain the primary access point for oral analgesics, antispasmodics, and standard IBS prescriptions. Online pharmacies are forecast to grow at an 8.92% CAGR through 2032. Specialty medicine sales reached USD 417 billion in 2024, according to the HDA Research Foundation, reflecting the expanding importance of specialty distribution. Digital fulfillment platforms also support prior authorization, patient engagement, adherence services, and payer coordination. These functions are important for biologics and targeted immunotherapies with complex reimbursement needs in the visceral pain treatment market. Hospital pharmacies remain essential for intravenous induction and infusion-based treatment.

Online growth is not limited to general retail dispensing. The channel increasingly separates into general online pharmacies and specialty platforms that manage limited-distribution drugs, cold-chain handling, and hub services. This distinction increases the revenue contribution of specialty prescriptions relative to commodity analgesics. It also gives manufacturers a reason to partner with distributors that can provide patient support and data services. Retail pharmacies will continue to serve the larger volume of routine prescriptions. The visceral pain treatment market therefore requires channel strategies that reflect product complexity rather than simply prescription volume. Companies that can integrate reimbursement support with reliable delivery may secure a stronger position in the specialty segment.

By End User:

Specialty Clinics Expand the Site of Care

Hospitals accounted for 46.39% of market share in 2026, supported by acute management of IBD flares, pancreatitis, and diagnostic workups. Specialty clinics are forecast to expand at a 9.36% CAGR through 2032. Hospitals remain important for intravenous biologic induction and multidisciplinary care that involves gastroenterology, urology, and pain specialists. They also manage patients with severe symptoms or diagnostic complexity. Specialty clinics benefit as maintenance treatment, monitoring, and self-injection education shift to outpatient settings. The HDA Research Foundation reports that specialty distributor networks serve more than 32,800 provider locations.

The site-of-care shift reflects changes in long-term IBD management across the visceral pain treatment market. Patients who achieve early deep remission may require fewer acute interventions and more structured follow-up. Outpatient clinics can offer flexible scheduling and lower overhead for maintenance treatment. They also align with patient-reported outcome monitoring used in specialist care. Ambulatory surgical centers retain a role in procedures such as celiac plexus blocks, spinal cord stimulation lead placement, and diagnostic laparoscopy. The visceral pain treatment industry will continue to rely on hospitals, but specialty clinics are gaining a larger role in ongoing care. This shift creates opportunities for providers and distributors that can support infusion, self-administration, and follow-up services.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Visceral Pain Treatment Market Share by End User, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Visceral Pain Treatment Market Share by End User, 2026

Geography Analysis

North America

North America held 37.45% of the share in 2026. High biologic use in IBD and a mature specialty pharmacy infrastructure support rapid access to limited-distribution therapies. LINZESS reached 234 million U.S. prescription capsules in 2025, supported by pediatric label expansion and market access execution. The FDA approval of JOURNAVX provides a non-opioid acute pain option in a region with substantial opioid exposure. FDA oversight and Medicare reimbursement policy shape adoption across the U.S.

Asia-Pacific

Asia-Pacific is forecast to expand at a 9.74% CAGR through 2032, the highest regional rate in the visceral pain treatment market. IBD incidence is increasing in China, India, and South Korea as urbanization, dietary changes, and diagnostic capacity advance. Lilly launched Omvoh in China in February 2026 following National Medical Products Administration approval for ulcerative colitis and Crohn's disease. Japan remains distinct because locally approved therapies such as ramosetron are used in IBS-D care under Japanese treatment practices. Payer capacity and access vary substantially across countries in the visceral pain treatment market.

Regional Diversification Beyond Core Markets

Europe remains a major part of the visceral pain treatment market because Western Europe recorded an age-standardized IBD prevalence of 348.4 per 100,000 in Global Burden of Disease 2021 data. The European Medicines Agency's centralized process can support access to new biologics across major European markets. South America is developing from a lower base as IBD awareness and gastroenterology infrastructure improve, particularly in Brazil and Argentina. The Middle East and Africa remain earlier-stage areas due to specialist shortages and diagnostic constraints.

Visceral Pain Treatment Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Visceral Pain Treatment Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The visceral pain treatment market is moderately concentrated in blockbuster IBD biologics but remains fragmented across analgesics, antispasmodics, and device-based treatment. AbbVie, Takeda, and Eli Lilly are important competitors in high-value IBD therapy. Large companies are extending established brands through formulation changes and indication expansion. Takeda's subcutaneous Entyvio pen gained 20% sequential U.S. volume growth in the first half of FY2025. AbbVie and Ironwood secured the November 2025 pediatric IBS-C label expansion for LINZESS.

AbbVie licensed NXE0033744 from Nxera Pharma in November 2026, committing USD 100 million upfront and potential development and commercial milestones. Its April 2025 collaboration with Parvus supports work on pMHC nanomedicine for IBD. These investments show how incumbents are building next-generation pipelines as exclusivity risk rises in the visceral pain treatment market. Ironwood stopped IW-3300 development for interstitial cystitis or bladder pain syndrome after Phase II analysis. The outcome shows the risk of expansion outside established IBS and IBD pathways.

Device companies are also adding competitive pressure. NeurAxis secured a Category I CPT code effective January 2026 for PENFS procedures. Alvotech reported positive pivotal pharmacokinetic results for AVT80, a proposed subcutaneous vedolizumab biosimilar, in February 2026. Biosimilars could compress revenue for established biologics and sharpen price competition in the visceral pain treatment market.

Visceral Pain Treatment Industry Leaders

  1. AbbVie Inc.

  2. AstraZeneca PLC

  3. Bayer AG

  4. Bristol Myers Squibb Company

  5. Eli Lilly and Company

  6. *Disclaimer: Major Players sorted in no particular order

Visceral Pain Treatment Market Companies Covered in this Report

  • Abbvie
  • AstraZeneca
  • Astellas Pharma
  • Addex Therapeutics Ltd
  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Endo International
  • GlaxoSmithKline
  • Grünenthal GmbH
  • Ironwood Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Viatris

Recent Industry Developments in Visceral Pain Treatment Market

  • November 2026: AbbVie entered an exclusive global license agreement with Nxera Pharma for NXE0033744, an investigational oral EP4 receptor agonist for IBD, paying USD 100 million upfront with eligibility for up to USD 1.37 billion in development and commercial milestones plus tiered royalties. The asset is a potential first-in-class GI-targeted molecule designed to selectively activate EP4 receptors locally in the GI tract, and the deal marks one of the highest-value early-phase IBD licensing transactions of 2026.
  • October 2025: NeurAxis was awarded FDA 510(k) clearance for its percutaneous electrical nerve field stimulation technology for functional abdominal pain associated with functional dyspepsia and nausea in patients aged 8 years and older. A Category I CPT code for the procedure became effective January 1, 2026, completing the clinical and reimbursement infrastructure needed for commercial scaling.
  • February 2025: Eli Lilly launched Omvoh, marketed as Antrolet, in China following National Medical Products Administration approval for moderately to severely active ulcerative colitis and Crohn's disease in adults, extending Omvoh's commercial footprint to 47+ countries.

Table of Contents for Visceral Pain Treatment Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Gastrointestinal and Pelvic Pain Disorders
    • 4.2.2 Shift Toward Non-Opioid and Mechanism-Based Therapies
    • 4.2.3 Expansion of IBS and IBD Diagnosis and Treatment Pathways
    • 4.2.4 FDA-Cleared Neuromodulation for Functional Abdominal Pain
    • 4.2.5 Growing Use of Biomarker-Guided and Personalized Treatment
    • 4.2.6 Increasing Access Through Specialty, Retail, and Digital Channels
  • 4.3 Market Restraints
    • 4.3.1 Diagnostic Ambiguity and Overlapping Pain Phenotypes
    • 4.3.2 Adverse Effects and Dependence Risk of Conventional Analgesics
    • 4.3.3 Limited Validated Biomarkers and Inconsistent Pain Endpoints
    • 4.3.4 Reimbursement and Evidence Gaps for Devices and Behavioral Care
  • 4.4 Value and Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Drug Class
    • 5.1.1 Analgesics
    • 5.1.2 Pain Modifiers
    • 5.1.3 Antispasmodics
    • 5.1.4 Biologics and Targeted Immunotherapies
    • 5.1.5 Others
  • 5.2 By Indication
    • 5.2.1 Irritable Bowel Syndrome
    • 5.2.2 Inflammatory Bowel Disease
    • 5.2.3 Chronic Pancreatitis
    • 5.2.4 Interstitial Cystitis and Bladder Pain Syndrome
    • 5.2.5 Chronic Prostatitis and Chronic Pelvic Pain Syndrome
    • 5.2.6 Others
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Injectable and Infusion
    • 5.3.3 Topical
    • 5.3.4 Others
  • 5.4 By Distribution Channel
    • 5.4.1 Hospital Pharmacies
    • 5.4.2 Retail Pharmacies
    • 5.4.3 Online Pharmacies
    • 5.4.4 Others
  • 5.5 By End User
    • 5.5.1 Hospitals
    • 5.5.2 Specialty Clinics
    • 5.5.3 Ambulatory Surgical Centers
    • 5.5.4 Others
  • 5.6 By Geography
    • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
    • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
    • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
    • 6.3.1 AbbVie Inc.
    • 6.3.2 AstraZeneca PLC
    • 6.3.3 Astellas Pharma Inc.
    • 6.3.4 Addex Therapeutics Ltd
    • 6.3.5 Amgen Inc.
    • 6.3.6 Bayer AG
    • 6.3.7 Bristol Myers Squibb Company
    • 6.3.8 Eli Lilly and Company
    • 6.3.9 Endo International plc
    • 6.3.10 GlaxoSmithKline plc
    • 6.3.11 Grünenthal GmbH
    • 6.3.12 Ironwood Pharmaceuticals Inc.
    • 6.3.13 Johnson & Johnson
    • 6.3.14 Merck & Co., Inc.
    • 6.3.15 Novartis AG
    • 6.3.16 Pfizer Inc.
    • 6.3.17 Sanofi S.A.
    • 6.3.18 Takeda Pharmaceutical Company Limited
    • 6.3.19 Teva Pharmaceutical Industries Ltd
    • 6.3.20 Viatris Inc.

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment

Global Visceral Pain Treatment Market Report Scope

As per the scope of the report, visceral pain treatment refers to the medical management of pain that originates from the internal organs (viscera), such as the gastrointestinal tract, urinary bladder, pancreas, uterus, or other abdominal and pelvic organs. Visceral pain is typically caused by inflammation, distension, ischemia, obstruction, or abnormal contractions of internal organs and is often described as deep, diffuse, cramping, or poorly localized.

The visceral pain treatment market is segmented by drug class, indication, route of administration, distribution channel,  end user, and geography. By drug class, the market is segmented into analgesics, pain modifiers, antispasmodics, biologics & targeted immunotherapies, and others. By indication, the market is segmented into irritable bowel syndrome, inflammatory bowel disease, chronic pancreatitis, interstitial cystitis and bladder pain syndrome, chronic prostatitis & chronic pelvic pain syndrome, and others. By route of administration, the market is segmented into oral, injectable & infusion, topical, and others. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. By end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers estimated market sizes and market trends for 17 countries across major regions worldwide. The report offers market value (in USD) for the above segments.

Segmentation Overview

By Drug Class
Visceral Pain Treatment Market segmentation breakdown
Analgesics
Pain Modifiers
Antispasmodics
Biologics and Targeted Immunotherapies
Others
By Indication
Visceral Pain Treatment Market segmentation breakdown
Irritable Bowel Syndrome
Inflammatory Bowel Disease
Chronic Pancreatitis
Interstitial Cystitis and Bladder Pain Syndrome
Chronic Prostatitis and Chronic Pelvic Pain Syndrome
Others
By Route of Administration
Visceral Pain Treatment Market segmentation breakdown
Oral
Injectable and Infusion
Topical
Others
By Distribution Channel
Visceral Pain Treatment Market segmentation breakdown
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By End User
Visceral Pain Treatment Market segmentation breakdown
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others
By Geography
Visceral Pain Treatment Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Visceral Pain Treatment Market segmentation breakdown
By Drug Class Analgesics
Pain Modifiers
Antispasmodics
Biologics and Targeted Immunotherapies
Others
By Indication Irritable Bowel Syndrome
Inflammatory Bowel Disease
Chronic Pancreatitis
Interstitial Cystitis and Bladder Pain Syndrome
Chronic Prostatitis and Chronic Pelvic Pain Syndrome
Others
By Route of Administration Oral
Injectable and Infusion
Topical
Others
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By End User Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is the projected value of visceral pain treatment by 2032?

The value is forecast to reach USD 25.03 billion by 2032 from USD 16.83 billion in 2026, at a 6.84% CAGR.

Which drug class is growing fastest for visceral pain treatment?

Biologics and targeted immunotherapies are projected to grow at a 7.21% CAGR through 2032, supported by IBD treatment adoption.

Which condition has the largest share of treatment demand?

Irritable bowel syndrome held 34.15% share in 2026, while IBD is the fastest-growing indication at a 7.57% CAGR.

Why are non-opioid pain therapies becoming more important?

Safety concerns and dependence risk limit long-term opioid use, while the FDA approval of JOURNAVX has increased attention on selective non-opioid pain mechanisms.

Which care setting is expected to grow most quickly?

Specialty clinics are projected to grow at a 9.36% CAGR through 2032 as maintenance biologic care moves toward outpatient settings.

Which region is forecast to grow fastest?

Asia-Pacific is projected to expand at a 9.74% CAGR through 2032 as IBD diagnosis and specialty treatment access improve.

Page last updated on: